$RSMDF

RESMED INC

CIK:0000943819|SEC Filings

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2024
Net revenue	$ 5,653,443	$ 5,146,327	$ 4,685,297
Cost of sales (exclusive of amortization shown separately below)	2,169,925	2,059,241	1,997,031
Amortization of acquired intangible assets	31,779	32,116	32,963
Total cost of sales	2,201,704	2,091,357	2,029,994
Gross profit	3,451,739	3,054,970	2,655,303
Operating Expenses
Research and development	378,285	331,284	307,525
Selling, general, and administrative	1,119,528	993,050	917,136
Amortization of acquired intangible assets	45,466	45,273	46,521
Restructuring expenses (note 17)	21,745	0	64,228
Total operating expenses	1,565,024	1,369,607	1,335,410
Income from operations	1,886,715	1,685,363	1,319,893
Other income (loss), net:
Interest income (expense), net	49,914	4,114	(45,708)
Gain (loss) attributable to equity method investments (note 6)	6,955	3,644	(1,848)
Gain (loss) on equity investments (note 6)	(15,014)	(10,299)	(4,045)
Other, net	(9,154)	(5,256)	(3,494)
Total other income (loss), net	32,701	(7,797)	(55,095)
Income before income taxes	1,919,416	1,677,566	1,264,798
Income taxes (note 12)	396,123	276,843	243,847
Net income	$ 1,523,293	$ 1,400,723	$ 1,020,951
Basic earnings per share (note 11) (in dollars per share)	$ 10.47	$ 9.55	$ 6.94
Diluted earnings per share (note 11) (in dollars per share)	10.43	9.51	6.92
Dividend declared per share (in dollars per share)	$ 2.40	$ 2.12	$ 1.92
Basic shares outstanding (000's) (in shares)	145,523	146,716	147,021
Diluted shares outstanding (000's) (in shares)	146,054	147,340	147,550
Sleep and Breathing Health
Net revenue	$ 4,977,630	$ 4,504,890	$ 4,101,172
Cost of sales (exclusive of amortization shown separately below)	1,962,607	1,864,198	1,806,845
Amortization of acquired intangible assets	6,266	6,646	5,515
Residential Care Software
Net revenue	675,813	641,437	584,125
Cost of sales (exclusive of amortization shown separately below)	207,318	195,043	190,186
Amortization of acquired intangible assets	$ 25,513	$ 25,470	$ 27,448

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net income	$ 1,523,293	$ 1,400,723	$ 1,020,951
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	201,342	198,473	176,870
Amortization of right-of-use assets	42,810	37,338	39,339
Stock-based compensation costs (note 10)	104,348	91,661	80,184
(Gain) loss attributable to equity method investments, net of dividends received (note 6)	(2,382)	(3,644)	1,848
(Gain) loss on equity investments (note 6)	15,014	10,299	4,045
Gain on previously held equity investment (note 6)	(4,353)	0	0
Restructuring expenses (note 17)	0	0	33,239
Changes in operating assets and liabilities:
Accounts receivable	(96,778)	(76,684)	(134,278)
Inventories	(9,920)	(80,165)	172,203
Prepaid expenses, net deferred income taxes and other current assets	(140,260)	82,629	(115,213)
Accounts payable, accrued expenses and other	172,715	90,958	122,072
Net cash provided by (used in) operating activities	1,805,829	1,751,588	1,401,260
Cash flows from investing activities:
Purchases of property, plant and equipment	(156,285)	(89,865)	(99,460)
Patent registration costs	(18,670)	(10,777)	(15,396)
Purchases of intangible assets	(2,218)	0	0
Business acquisitions, net of cash acquired	(350,724)	(139,248)	(133,464)
Purchases of investments (note 6)	(28,536)	(6,416)	(12,765)
Proceeds from exits of investments (note 6)	2,752	4,628	1,000
Proceeds (payments) on maturity of foreign currency contracts	8,482	41,633	(9,699)
Net cash provided by (used in) investing activities	(545,199)	(200,045)	(269,784)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	74,503	74,439	53,094
Taxes paid related to net share settlement of equity awards	(21,833)	(18,077)	(8,757)
Purchases of treasury stock	(700,037)	(300,025)	(150,011)
Payments of business combination contingent consideration	0	(855)	(1,293)
Acquisition of consolidated subsidiary	0	(10,855)	0
Proceeds from borrowings, net of borrowing costs	0	0	105,000
Repayment of borrowings	(10,000)	(40,000)	(835,000)
Dividends paid	(349,662)	(310,880)	(282,320)
Net cash provided by (used in) financing activities	(1,007,029)	(606,253)	(1,119,287)
Effect of exchange rate changes on cash	6,183	25,799	(1,719)
Net increase (decrease) in cash and cash equivalents	259,784	971,089	10,470
Cash and cash equivalents at beginning of period	1,209,450	238,361	227,891
Cash and cash equivalents at end of period	1,469,234	1,209,450	238,361
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	357,167	214,013	278,400
Interest paid	27,057	28,415	45,708
Fair value of assets acquired, excluding cash	151,186	43,534	46,033
Liabilities assumed	(11,841)	(6,279)	(7,696)
Goodwill on acquisition	222,933	101,323	92,191
Previously held equity investment	(7,353)	0	0
Deferred payments	(1,030)	670	(143)
Fair value of contingent consideration	(3,171)	855	4,372
Cash paid for acquisitions	$ 350,724	$ 140,103	$ 134,757

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Current assets:
Cash and cash equivalents	$ 1,469,234	$ 1,209,450
Accounts receivable, net of allowances of $25,839 and $22,424 ‎at June 30, 2026 and June 30, 2025, respectively	1,036,233	939,492
Inventories (note 4)	945,805	927,711
Prepaid expenses and other current assets (note 4)	416,081	428,952
Assets held for sale (note 18)	457,386	0
Total current assets	4,324,739	3,505,605
Non-current assets:
Property, plant and equipment, net (note 4)	581,829	550,790
Operating lease right-of-use assets (note 9)	153,167	167,497
Goodwill (note 5)	2,909,575	3,046,680
Other intangible assets, net (note 5)	452,737	464,861
Deferred income taxes (note 12)	329,254	253,119
Prepaid taxes and other non-current assets	214,649	185,839
Total non-current assets	4,641,211	4,668,786
Total assets	8,965,950	8,174,391
Current liabilities:
Accounts payable	308,923	278,157
Accrued expenses (note 7)	494,921	402,253
Operating lease liabilities, current (note 9)	29,141	30,506
Deferred revenue	162,911	166,030
Income taxes payable (note 12)	98,108	132,274
Short-term debt, net (note 8)	259,950	9,900
Liabilities held for sale (note 18)	41,156	0
Total current liabilities	1,395,110	1,019,120
Non-current liabilities:
Deferred revenue	170,951	156,803
Deferred income taxes (note 12)	64,640	77,682
Operating lease liabilities, non-current (note 9)	137,413	153,015
Other long-term liabilities	213,028	141,520
Long-term debt, net (note 8)	399,415	658,392
Total non-current liabilities	985,447	1,187,412
Total liabilities	2,380,557	2,206,532
Commitments and contingencies (note 15)
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	0	0
Common stock, $0.004 par value, 350,000,000 shares authorized; ‎191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and ‎190,311,097 issued and 146,385,350 outstanding at June 30, 2025	764	761
Additional paid-in capital	2,190,614	2,033,599
Retained earnings	7,255,121	6,081,490
Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025	(2,778,591)	(2,073,292)
Accumulated other comprehensive loss	(82,515)	(74,699)
Total stockholders’ equity	6,585,393	5,967,859
Total liabilities and stockholders’ equity	$ 8,965,950	$ 8,174,391